Posted by Michael Wonder on 08 May 2018
Precision medicines have faster approvals based on fewer and smaller trials than other medicines
7 May 2018 - Precision medicines can benefit patients by increasing the probability of a successful treatment response in selected patient populations.
The potential for more immediate signals of efficacy during clinical trials suggests such medicines will reach the market more rapidly than traditional drugs will.
Using data from the FDA, we examined the regulatory review and pivotal trial characteristics of precision medicines. We found that in the period January 2013–June 2017, precision medicines were developed and reviewed almost two years faster than non-precision medicines.
